openPR Logo
Press release

Escherichia coli Infections (Infectious Disease) Pipeline Landscape Report, H1, 2017 - Pharmaceutical Disease Pipeline Guide

06-02-2017 05:07 PM CET | Health & Medicine

Press release from: Pharmaceutical Research Reports [MRH]

Market Research Hub

Market Research Hub

Market Research Hub's Pharmaceutical and Healthcare latest pipeline guide Escherichia coli Infections - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Escherichia coli Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

Request Free Sample Report @ http://www.marketresearchhub.com/enquiry.php?type=S&repid=1107570

Escherichia coli (E. coli) bacteria normally live in the intestines of healthy people and animals. Escherichia coli infections are caused by coming into contact with the feces, or stool, of humans or animals or drink water or eat food that has been contaminated by feces. Symptoms include diarrhea, which may range from mild and watery to severe and bloody, abdominal cramping, pain or tenderness, nausea and vomiting. The predisposing factors include age, weakened immune systems and eating certain types of food like undercooked hamburger, unpasteurized milk, apple juice or cider and soft cheeses made from raw milk. Treatment includes antibiotics and healthy life style.
The Escherichia coli Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Escherichia coli Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 2, 2, 30 and 13 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 2, 5 and 15 molecules, respectively.

Escherichia coli Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Escherichia coli Infections (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Escherichia coli Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Escherichia coli Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Escherichia coli Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Escherichia coli Infections (Infectious Disease)

Reasons to Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Escherichia coli Infections (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Escherichia coli Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Browse Full Report with TOC @ http://www.marketresearchhub.com/report/escherichia-coli-infections-pipeline-review-h1-2017-report.html

Table of Contents:
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 7
Global Markets Direct Report Coverage 7
Escherichia coli Infections - Overview 8
Escherichia coli Infections - Therapeutics Development 9
Pipeline Overview 9
Pipeline by Companies 10
Pipeline by Universities/Institutes 14
Products under Development by Companies 16
Products under Development by Universities/Institutes 19
Escherichia coli Infections - Therapeutics Assessment 21
Assessment by Target 21
Assessment by Mechanism of Action 23
Assessment by Route of Administration 25
Assessment by Molecule Type 27
Escherichia coli Infections - Companies Involved in Therapeutics Development 29
Abgentis Ltd 29
Adenium Biotech ApS 29
AstraZeneca Plc 30
Atterx Biotherapeutics Inc 30
AvidBiotics Corp 31
Cellceutix Corp 31
ContraFect Corp 32
Debiopharm International SA 32
Emergent BioSolutions Inc 33
F. Hoffmann-La Roche Ltd 33
GangaGen Inc 34
Hsiri Therapeutics LLC 34
ImmunoClin Corp 35
Immuron Ltd 35
Johnson & Johnson 36
Kyorin Pharmaceutical Co Ltd 36
Melinta Therapeutics Inc 37

About Market Research Hub:
Market Research Hub (MRH) is a next-generation reseller of research reports and analysis. MRH’s expansive collection of market research reports has been carefully curated to help key personnel and decision makers across industry verticals to clearly visualize their operating environment and take strategic steps.

MRH functions as an integrated platform for the following products and services: Objective and sound market forecasts, qualitative and quantitative analysis, incisive insight into defining industry trends, and market share estimates. Our reputation lies in delivering value and world-class capabilities to our clients.

Contact Details:
90 State Street,
Albany, NY 12207,
United States
Toll Free: 866-997-4948 (US-Canada)
Tel: +1-518-621-2074
Email: press@marketresearchhub.com
Website: http://www.marketresearchhub.com/
Follow Us on:
Twitter: https://twitter.com/MktResearchHub/
LinkedIn: https://www.linkedin.com/company/market-research-hub/
Facebook: https://www.facebook.com/MarketResearchHub/

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Escherichia coli Infections (Infectious Disease) Pipeline Landscape Report, H1, 2017 - Pharmaceutical Disease Pipeline Guide here

News-ID: 561760 • Views: 125

More Releases from Pharmaceutical Research Reports [MRH]

Pipeline Analysis on Phenylalanine 4 Hydroxylase Reviewed by Company, Profiled D …
Market Research Hub (MRH) has recently publicized a new study to its vast repository, which is titled as “Phenylalanine 4 Hydroxylase (Phe 4 Monooxygenase or PAH or EC 1.14.16.1) - Pipeline Review, H1 2017”. This research study outlays comprehensive information on the Phenylalanine 4 Hydroxylase (Phe 4 Monooxygenase or PAH or EC 1.14.16.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration
Aminopeptidase N (Myeloid Plasma Membrane Glycoprotein CD13 or Alanyl Aminopepti …
According to the latest pipeline analysis, Aminopeptidase N (APN/CD13) acts as an exopeptidase and has been studied for decades. In recent years, it has been seen not only as a tumor-related target but also as a potential functional protein in various other physiological or pathological processes, such as analgesia, virus infection and inflammation. To elaborate further details on its global demand, a study titled “Aminopeptidase N (Myeloid Plasma Membrane Glycoprotein
Global Indoleamine 2, 3 Dioxygenase 1 Industry Vital Pipeline Review for the Fir …
The indoleamine 2, 3 Dioxygenase 1 or IDO1 market is developing since the cancer treatment sector relies heavily on its’ in-depth research and high-quality treatments. Looking into this huge potential, a new study has been added to the vast online repository of Market Research Hub (MRH), with the title ‘’Indoleamine 2, 3 Dioxygenase 1 (Indoleamine Pyrrole 2, 3 Dioxygenase 1 or IDO1 or EC 1.13.11.52) - Pipeline Review, H1 2017‘’.
Prosthetic Joint Infections - Clinical Trials Rise Due to Higher Disease Inciden …
Market Research HUB's Pharmaceutical and Healthcare latest pipeline guide Prosthetic joint infections - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Prosthetic joint infections (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news

All 5 Releases


More Releases for Escherichia

Escherichia Coli (E. Coli) Diagnostic Testing Market Pitching Growth by 2021
Escherichia coli (E. coli), is a bacterium which normally lives in the intestines of humans and animals. Some types of E. coli are an important part of a healthy human intestinal system. However, others are pathogenic and can cause illness and diarrhea. E. coli that cause diarrhea can be transmitted through contaminated water and food or through contact with animals or persons. Pathogenic E. coli strains are categorized into pathotypes.
Escherichia Coli Diagnostic Testing Market to Register Substantial Expansion by …
Escherichia coli (E. coli), is a bacterium which normally lives in the intestines of humans and animals. Some types of E. coli are an important part of a healthy human intestinal system. However, others are pathogenic and can cause illness and diarrhea. E. coli that cause diarrhea can be transmitted through contaminated water and food or through contact with animals or persons. Pathogenic E. coli strains are categorized into pathotypes.
Escherichia coli Infections Pipeline Research and Therapeutic Development Review …
Market Research Hub (MRH) has recently broadcasted a new study to its broad research portfolio, which is titled as “Escherichia coli Infections - Pipeline Review, H2 2017”, report studies Escherichia coli (E. coli) bacteria normally live in the intestines of healthy people and animals. Escherichia coli infections are caused by coming into contact with the feces, or stool, of humans or animals or drink water or eat food that has
Escherichia Coli (E. Coli) Diagnostic Testing Market Explores New Growth Opportu …
Escherichia coli (E. coli), is a bacterium which normally lives in the intestines of humans and animals. Some types of E. coli are an important part of a healthy human intestinal system. However, others are pathogenic and can cause illness and diarrhea. E. coli that cause diarrhea can be transmitted through contaminated water and food or through contact with animals or persons. Pathogenic E. coli strains are categorized into pathotypes.
Escherichia Coli (E. Coli) Diagnostic Testing Market to Register Unwavering Grow …
Escherichia coli (E. coli), is a bacterium which normally lives in the intestines of humans and animals. Some types of E. coli are an important part of a healthy human intestinal system. However, others are pathogenic and can cause illness and diarrhea. E. coli that cause diarrhea can be transmitted through contaminated water and food or through contact with animals or persons. Pathogenic E. coli strains are categorized into pathotypes.
Global Escherichia Coli (E. Coli) Diagnostic Testing Market
The Escherichia Coli Diagnostic Testing Market report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies. Escherichia coli (E. coli), is a bacterium which normally lives in the intestines of humans and animals. Some types of E. coli are an important part of a healthy